title: Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report.
abstract: Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia. However, information concerning clinical experience and management of severe neutropenia is currently limited. In this report, the successful management of crizotinib-induced neutropenia by dose reduction of crizotinib in a patient with ALK-positive non-small cell lung cancer is described.
authors.affiliation: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Osugi
authors.affiliation: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Owada
authors.affiliation: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
authors.forename: Takumi
authors.initials: T
authors.lastname: Yamaura
authors.affiliation: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Muto
authors.affiliation: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Okabe
authors.affiliation: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Matsumura
authors.affiliation: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Higuchi
authors.affiliation: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Suzuki
authors.affiliation: Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan.
authors.forename: Mitsukazu
authors.initials: M
authors.lastname: Gotoh
keywords: Alectinib; Anaplastic lymphoma kinase gene rearrangement; Crizotinib; Neutropenia; Non-small cell lung cancer